Delaware Judiciary Town Hall

Alfred E. Bacon, III MD FACP May 24, 2021




COVID 19-Topics

- Current epidemic curve and status
- Variant data—extent/new strains/clinical data
- Vaccination numbers
- Approach issue of vaccine hesitancy—cautious area
- CDC guidelines for distancing/masks/activity

Case Presentation

- 87 female, lymphoma, ctx (1 month ago)
- 4 weeks out from Moderna vax
- Lives with family
- 4 days SOB, fatigue, dx pna
- EMS called to home, CPR in progress
- Survived , Admitted to MICU, intubated, pressor support
- Refractory respiratory failure, cardiac arrest
- Comfort care initiated


Daily Trends in Number of COVID-19 Cases in the United States Reported to CDC



Source: CDC.gov 5/20/21

New cases of Covid-19, reported to CDC, in DE

Seven-day moving average of new cases, by number of days since 10



Source: CDC 5/20/21

COVID-19 Data Dashboard Overview

View all COVID-19 data →

56.8%

Delawareans 16+ With at Least 1 Vaccine Dose

119

New Cases 7-day Average

849,861

Vaccines Administered


73 Current Hospitalizations

1,652


Total Deaths 13.3 per 10,000 people 3.5%

Positive Tests 7-day Average

CASES WHO VISITED VENUES (REPORTED ALL WEEKS)



Change in Daily U.S. Covid-19 Cases and Deaths Since Jan. 1



the National Institute of Allergy and Infectious Diseases.

Variant	First identified in	More contagious?	Ability to evade vaccine	CDC/WHO classification
B.1.1.7	United Kingdom	Yes	Minimal	Concern
B.1.351	South Africa	Yes	Moderate	Concern
P.1	Brazil	Yes	Moderate	Concern
B.1.526	New York	Unknown	Potentially	Interest
B.1.525	New York	Unknown	Potentially	Interest
P.2	Brazil	Unknown	Potentially	Interest
B.1.427	California	Yes	Moderate	Concern
B.1.429	California	Yes	Moderate	Concern
P.3	Philippines	Unknown	Unknown	Under investigation
A.23.1 with E484K	England	Unknown	Unknown	Under investigation
B.1.1.7 with E484K	England	Unknown	Unknown	Under investigation
B.1.525	England	Unknown	Unknown	Under investigation
B1.1.318	Unknown	Unknown	Unknown	Under investigation
B1.324.1 with E383K	Unknown	Unknown	Unknown	Under investigation
B.1.111 with E383K and 429S	Columbia	Unknown	Unknown	Unknown

Known genetic variants of SARS-CoV-2

Sources: Rappler.com, CDC.gov, Health.com, WHO Weekly Epidemiological Update, Public Health England

COVID 19 VARIANTS

- B117 remains dominant in Delaware
- 1351 (SA) increasing
- India variant now present
- All vaccines active vs B117
- AZ less active vs SA (1351)
- India variant highly concerning
- Variant issue ----- rapid spread, increased virulence, high load

		Author	ized for Emergency Use in th	ur Local Epidemiologi e U.S.		III U.S. Trials Underway	
		Pfizer	Moderna	J&J One-Dose	AstraZeneca	Novavax	J&J Two-Dose
	Biotechnology	mRNA	mRNA	Adenovirus	Adenovirus	Recombinant protein	Adenovirus
	Months of available RCT data	6 months	6 months	3 months			
	Overall efficacy (old variants)	Adults 95% (clinical trial) 91%; 85% after dose 1 (real world -Israel) 90%; 80% after dose 1 (rea world- US) Adolescents 100% (clinical trial)	94.1% (clinical trial) 90%; 80% after dose 1 (real world- US)	66.1% (global clinical trial) 72.0% (U.S. clinical trial) 76.7% (real world)	U.S. numbers: 76% (clinical trial) Outside U.S. numbers: 62% (clinical trials) 67% (real world) 82% when doses were ≥12 weeks apart and 55% when doses were <6 weeks apart	96.4%	
	Efficacy (old variants) among 65+	92.9% (65-75) 100% (75+)	100%	68.6% (global)	85%		
D19	B.1.1.7 (UK) variant	87-95% efficacy (Israel and Qatar)	Vaccine works (No impact on neutralizing antibodies)		74% efficacy	86.3% efficacy	
Symptomatic COVID19	B.1.351 (S. Africa) variant	72-75% efficacy (Qatar)	Vaccine works (6-fold decrease in neutralizing antibodies; T- cells working)	52-57% efficacy	Vaccine does not work against mild-to-moderate disease 10-22% efficacy (9.5-fold decrease in neutralizing antibodies)	55.4% efficacy among HIV- participants; 48.6% overall	
	P.1 (Brazil) variant	Vaccine works (Neutralizing antibodies only slightly reduced T-cells working)	Vaccine works (Neutralizing antibodies only slightly reduced T-cells working)	51% efficacy	Probably reflective of B.1.351 findings	Probably reflective of B.1.351 findings	
	B.1.427/B.1.429 (CA) variant	Vaccine works (3-4 fold decrease in neutralizing antibodies T-cells working)	Vaccine works (3-4 fold decrease in neutralizing antibodies T-cells working)	Unknown	Unknown	Unknown	
	B.1.526 (NY) variant	Vaccine works (4.5-fold decrease in neutralizing antibodies)	Vaccine works (4.5-fold decrease in neutralizing antibodies)	Unknown	Unknown	Unknown	
	B.1.617 (India) double mutant	Unknown	Unknown	Unknown	Unknown	Unknown	
Severe COVID19	Protection from severe disease	90% (clinical trial) 97-100% (real world-S. Africa, Qatar)	100%	85% (100% after day 49)	100%	100%	
CO.	Protection from hospitalization	100% clinical trials 94% real world (US)	100% clinical trials 94% real world (US)	100% clinical trials	100% clinical trials	100% clinical trials	
Seven	Protection from death	100% elinical trials 97-99.99% real world (Israel, Qatar)	100% clinical trials	100% clinical trials	100% clinical trials	100% clinical trials	
	Contingency plan for variants	Developing booster	Booster trial against B.1.351 started	Developing updated vaccine	Developing updated vaccine	Developing updated vaccine	
	Asymptomatic (transmission) reduction**	72-95%	67-72%	74%	2% (SD/SD); 49% (among LD/SD)		
	Age	16+	18+	18+ (FDA warning for blood clots)	18+	18+	18+
	# doses	2 (3 weeks apart)	2 (4 weeks apart)	1	2 (4 weeks apart)	2 (3 weeks apart)	2 (4 weeks apart)
	Storage	-25 to -15 C	-25 to -15 C	2°C to 8°C	2°C to 8°C	2°C to 8°C	2°C to 8°C
	Status of pediatric trials	Adolescent complete Child started	Adolescent ongoing Child started standard dose; J&J=Johnson a	Enrollment will start ages 6mo-11y soon	Enrollment open in UK for 6+ years	Enrollment open	

COVID19 Vaccine Update- May 7, 2021 By: Your Local Epidemiologist

VACCINATIONS IN DELAWARE

FULLY VACCINATED KEY METRICS

321,194

Total Persons with 2 Doses of 2-Dose Series

More details about second doses

33,697

Total Persons with 1 Dose of 1-Dose Series


More details about 1-dose vaccines


PARTIALLY VACCINATED KEY METRICS

89,407

Total Persons with only 1 Dose of 2-Dose Series

Persons Partially Vaccinated = persons starting a 2-dose vaccination series. Persons Fully Vaccinated = persons completing a 1 or 2-dose vaccination series.






State of Delaware COVID 19 Vaccinations

VACCINE CAMPAIGN KEY METRICS

People Vaccinated	At Least One Dose	Fully Vaccinated
All ages	<mark>444,31</mark> 7	354,89 <mark>1</mark>
Percentage of people of all ages	46.4%	37.1%
16+ age group	<mark>4</mark> 41,038	354,838
Percentage of 16+ age group	56 <mark>.</mark> 8%	45.7%
65+ age group	15 <mark>5,02</mark> 9	138,065
Percentage of 65+ age group	89.0%	79.3%






* Assuming vaccinations continue at current rate of 0.6% of adults per day receiving their first dose

* Calculated based on Surgo's nationally representative survey of 1,670 adults in the United States from March 18-March 25, 2021 Source: Surgo Ventures

Vaccine Hesitancy – national map



Source CDC.gov 5/20/21

Table 1. Incident SARS-CoV-2 Infection among Nursing Home Residents According to Vaccination Status.*				
Variable	Total	Asymptomatic SARS-CoV-2 Infection	Symptomatic SARS-CoV-2 Infection	Percent of Infected Residents Who Were Asymptomatic
Residents vaccinated with ≥1 dose				
No. of residents	18,242			
Positive test after receipt of first dose — no. (%)				
At 0–14 days	822 (4.5)	587 (3.2)	235 (1.3)	71.4
At 15–28 days	250 (1.4)	179 (1.0)	71 (0.4)	71.6
Residents vaccinated with 2 doses				
No. of residents	13,048			
Positive test after receipt of second dose — no. (%)				
At 0–14 days	130 (1.0)	110 (0.8)	20 (0.2)	84.6
At >14 days	38 (0.3)	29 (0.2)	9 (0.1)	76.3

Table 1. Incident SARS-CoV-2 Infection among Nursing Home Residents According to Vaccination Status.*				
Variable	Total	Asymptomatic SARS-CoV-2 Infection	Symptomatic SARS-CoV-2 Infection	Percent of Infected Residents Who Were Asymptomatic
Unvaccinated residents				
No. of residents	3,990			
Positive test after first vaccination clinic — no. (%)				
At 0–14 days	173 (4.3)	115 (2.9)	58 (1.5)	66.5
At 15–28 days	69 (1.7)	42 (1.1)	27 (0.7)	60.9
At 29–42 days	16 (0.4)	13 (0.3)	3 (0.1)	81.2
At >42 days	12 (0.3)	10 (0.3)	2 (0.1)	83.3

COVID-19 vaccination will help keep you from getting COVID-19

- All COVID-19 vaccines currently available in the United States have been shown to be safe and effective at preventing COVID-19.
- All COVID-19 vaccines that are in development are being carefully evaluated in clinical trials and will be authorized or approved only if they make it substantially less likely you will get COVID-19.
- Based on what we know about vaccines for other diseases and early data from clinical trials, experts believe that getting a COVID-19 vaccine also helps keep you from getting seriously ill even if you do get COVID-19.
- Getting vaccinated yourself may also protect people around you, <u>particularly people at increased risk for severe</u> <u>illness from COVID-19</u>.
- Experts continue to conduct studies to learn more about how COVID-19 vaccination may reduce spread of the virus that causes COVID-19.

COVID-19 vaccination is a safer way to help build protection

- COVID-19 can have <u>serious, life-threatening complications</u>, and there is no way to know how COVID-19 will affect you.
 And if you get sick, you could spread the disease to friends, family, and others around you.
- Clinical trials for all vaccines must first show they are safe and effective before any vaccine can be authorized or approved for use, including COVID-19 vaccines. The known and potential benefits of a COVID-19 vaccine must outweigh the known and potential risks of the vaccine before it is used under what is known as an Emergency Use Authorization (EUA).
- Getting COVID-19 may offer some protection, known as natural immunity. Current evidence suggests that reinfection
 with the virus that causes COVID-19 is uncommon in the months after initial infection, but may increase with time.
 The risk of severe illness and death from COVID-19 far outweighs any benefits of natural immunity. COVID-19
 vaccination will help protect you by creating an antibody (immune system) response without having to experience
 sickness.
- Both natural immunity and immunity produced by a vaccine are important parts of COVID-19 disease that experts
 are trying to learn more about, and CDC will keep the public informed as new evidence becomes available.

Once you are fully vaccinated, you can start doing more

- <u>After you are fully vaccinated for COVID-19</u>, you may be able to start doing some things that you stopped doing because of the pandemic. For example, you can gather indoors without masks with other people who are fully vaccinated.
- People are not considered fully vaccinated until two weeks after their second dose of the <u>Pfizer-BioNTech</u> or <u>Moderna</u> COVID-19 vaccine, or two weeks after a single-dose <u>Johnson & Johnson's Janssen</u> COVID-19 vaccine. You should keep using all the tools available <u>to protect yourself and others</u> until you are fully vaccinated.

COVID-19 vaccination will be an important tool to help stop the pandemic

- Wearing masks and staying 6 feet apart from others help reduce your chance of being exposed to the virus or spreading it to others, but these measures are not enough. Vaccines will work with your immune system so it will be ready to fight the virus if you are exposed.
- A growing body of evidence suggests that fully vaccinated people are less likely to be infected without showing symptoms (called an asymptomatic infection) and potentially less likely to spread the virus that causes COVID-19 to others. However, further investigation is ongoing.
- Stopping a pandemic requires using all the tools we have available. As experts learn more about how COVID-19
 vaccination may help reduce spread of the virus that causes COVID-19, CDC will continue to update its
 recommendations to protect communities using the latest science.

Vaccine safety

Millions of people have safely received a COVID-19 vaccine

Over 272 million doses of COVID-19 vaccine have been given in the United States from December 14, 2020, through May 17, 2021.

COVID-19 vaccines are **safe and effective**. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical trials. The vaccines met FDA's rigorous scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization (EUA).



Millions of people in the United States have received COVID-19 vaccines, and these vaccines will undergo the most intensive safety monitoring in U.S. history. This monitoring includes using both established and new safety monitoring systems to make sure that COVID-19 vaccines are safe.

Source: CDC.gov 5/20/21

Common Side Effects

On the arm where you got the shot:



- Pain
- Redness
- Swelling



Tiredness

Throughout the rest of your body:

- Headache
- Muscle pain
- Chills
- Fever
- Nausea

To reduce pain and discomfort where you got the shot



- Apply a clean, cool, wet washcloth over the area.
- Use or exercise your arm.

To reduce discomfort from fever



- Drink plenty of fluids.
- Dress lightly.

Source: CDC.gov 5/20/21

May 2021- SURGO Survey

- Vaccine hesitancy National data
- 5 levels of acceptance
 - Enthusiast –varying time frame acceptance
 - Watchful 8%
 - Cost anxious 9%
 - System distrusters 4%
 - Science skeptics 14%

• SURGO VENTURES NY TIMES MAY 2021

Vaccine Persona	States with highest proportion of segment (% of the state adult population)
Enthusiasts	1. Vermont (18%) 2. North Carolina (14%) 3. Georgia (13%) 4. Tie: Louisiana (12%) and Utah (12%)
Watchful	1. Delaware (17%) 2. West Virginia (15%) 3. Oklahoma (14%) 4. Wyoming (13%) 5. Hawaii (12%)
Cost-Anxious	1. Mississippi (23%) 2. West Virginia (17%) 3. Alaska (16%) 4. Tie: Wyoming (14%) and Missouri (14%)
System Distrusters	1. Washington, DC (11%) 2. Georgia (8%) 3. Maryland (7%) 4. Tie: Michigan (6%) and Louisiana (6%)
COVID Skeptics	1. Arkansas (30%) 2. North Dakota (29%) 3. Wyoming (25%) 4. Louisiana (24%) 5. Idaho (23%)

COVID 19 Vaccine – adverse events

- Fever/myalgia/pain- up to 90%
- Anaphylaxis- 2-5 per million
- TTS (thrombosis/clots) 30 cases in 9.6 million doses
- Death .0017 %
- VAERS CDC reporting system

• CDC.GOV

ORIGINAL ARTICLE

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Tom T. Shimabukuro, M.D., Shin Y. Kim, M.P.H., Tanya R. Myers, Ph.D., Pedro L. Moro, M.D., Titilope Oduyebo, M.D., Lakshmi Panagiotakopoulos, M.D., Paige L. Marquez, M.S.P.H., Christine K. Olson, M.D., Ruiling Liu, Ph.D., Karen T. Chang, Ph.D., Sascha R. Ellington, Ph.D., Veronica K. Burkel, M.P.H., Ashley N. Smoots, M.P.H., Caitlin J. Green, M.P.H., Charles Licata, Ph.D., Bicheng C. Zhang, M.S., Meghna Alimchandani, M.D., Adamma Mba-Jonas, M.D., Stacey W. Martin, M.S., Julianne M. Gee, M.P.H., and Dana M. Meaney-Delman, M.D., for the CDC v-safe COVID-19 Pregnancy Registry Team*

New CDC Mask Guidelines

- Governor John Carney's most recent Modification to his State of Emergency order still requires mask-wearing in all State-owned buildings.
- This means mask are still required for all members of the public visiting our courthouses.





Executive Department Dover

TWENTY-NINTH MODIFICATION OF THE DECLARATION OF A STATE OF EMERGENCY FOR THE STATE OF DELAWARE DUE TO A PUBLIC HEALTH THREAT

WHEREAS on Sentember 3 2020 at 7:00 n m EDT. Licened the Twenty-Seventh

E. FACE COVERINGS.

1. Definitions. For purposes of this Twenty-Ninth Modification to the COVID-19 State of

Emergency declaration, the following terms shall have the meaning described herein:

i. "Face covering" means a cloth, paper, or disposable face covering that fully covers

122(3) 01 1100 10,

e. when they are a visitor at any state owned or operated facility open to the

public, unless otherwise specified herein;

Source: 29th Modification to State of Emergency

New CDC Mask Guidelines

Does the new CDC recommendation mean that if I am vaccinated I no longer have to wear a mask anywhere?

No. The CDC wants vaccinated people to wear masks in health-care settings and on planes, buses, trains and other public transportation. Also, everyone will have to abide by state and local mandates to wear masks where they remain in place. Businesses and other private entities can still require employees and patrons to wear masks, and some are likely to do so.

New CDC Mask Guidelines

• There are some exceptions to the mask mandate for Judicial Branch employees in their personal workspaces.

NOW, THEREFORE, IT IS ORDERED, effective 8:00 a.m. on May 21, 2021, that:

Source: DE Supreme Court Administrative Order No. 20 (1) Judicial branch employees must wear a face mask or covering when: speaking with any visitors to State court facilities, away from their designated workspace (except when eating or drinking in a break room or kitchen where three feet of physical distance can be consistently maintained), with other individuals in a workspace where a minimum of three feet of physical distance cannot be consistently maintained, and in a courtroom (except when speaking).

COURTHOUSE VACCINATION CLINCS



- May 25, 2021 9 a.m. to 12 p.m. Leonard Williams Justice Center, Wilmington
- May 27, 2021 9 a.m. to 11 a.m. Sussex County Courthouse, Georgetown
- May 27, 2021 12:30 a.m. to 1:30 p.m. Kent County Courthouse, Dover

